UK Registered Veterinary Retailer
Cytopoint

  • 10mg » 1ml Vial » Pack of 2 £70.49
  • 20mg » 1ml Vial » Pack of 2 £102.49
  • 30mg » 1ml Vial » Pack of 2 £142.00
  • 40mg » 1ml Vial » Pack of 2 £171.49

Selection of 4 products from

£70.49 to £171.49

Description

Cytopoint

This treatment applies to the following species:

Manufacturer: Zoetis

Canine Atopic Dermatitis Immunotherapeutic

For Use in Dogs Only

Cytopoint™ aids in the reduction of clinical signs associated with atopic dermatitis in dogs.

Cytopoint™ is a ready-to-use, sterile liquid containing a caninized monoclonal antibody (mAb) against interleukin-31 (IL-31). IL-31 has been shown to induce pruritus in dogs in laboratory studies.

Cytopoint™ remains in circulation for several weeks. It exerts a therapeutic effect by binding to and neutralizing soluble IL-31, thus inhibiting pruritus and reducing skin lesions. Like other naturally-occurring antibodies and antibody-antigen complexes, elimination is via normal protein degradation pathways.

SAFETY: A field safety study has demonstrated that Cytopoint™ is well tolerated in dogs after subcutaneous injection. Adverse events occurred at a similar frequency between treated and placebo groups in a study of 245 canine patients presented to veterinary hospitals and diagnosed with atopic dermatitis. In this study, dogs were administered Cytopoint™ (1.0-3.3 mg/kg body weight) or placebo by the subcutaneous route on Days 0 and 28. Signs of patient discomfort on administration and adverse events occurred at a similar frequency between treatment groups. In addition, there was no clinically important difference in clinical pathology changes between groups following either dose. A wide variety of concomitant medications were safely used, including parasiticides, antibiotics, antifungals, corticosteroids, vaccines, immunotherapy, antihistamines and other antipruritics, such as oclacitinib and cyclosporine.

This product is sourced in the United Kingdom and is intended for use in the United Kindgom only.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Mon - Fri: 8:30am - 5:00pm
  • Sat: 9:00am - 1:00pm (Collections only)
  • Email: [email protected]

All prices include VAT where applicable.

Medication Datasheets

10mg » 1ml Vial » Pack of 2

CYTOPOINT® solution for injection for dogs

Presentation

Each vial of 1 ml contains 10, 20, 30 or 40 mg Lokivetmab.

Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.

Uses

Indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For subcutaneous use. Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.

Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer in a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.

Dosage and treatment schedule

The recommended minimum dose is 1 mg/kg bodyweight, once a month. Dose according to the dosing chart below:

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 3 kg bodyweight.

Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.

In cases of atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

It is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.

If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation; therefore its use is not recommended during pregnancy, lactation or in breeding animals.

No drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.

If a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab administration.

Do not mix with any other veterinary medicinal product.

Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases. In such cases appropriate treatment should be administered immediately.

The frequency of adverse reactions is defined using the following convention:

No adverse reactions other than those mentioned above were observed in laboratory overdose studies. In case of adverse clinical signs after an overdose the dog should be treated symptomatically.

User warnings

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection.

Accidental self-injection may result in an immune response to lokivetmab. It is not expected for this to cause any adverse effects, however, repeated self-administration may increase the risk of hypersensitivity reactions.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Store in the original package. Protect from light.

Shelf life after first opening the immediate packaging: use immediately

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in boxes with 2 or 6 single dose vials.

Not all pack sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Not applicable.

Further information

Lokivetmab is a caninised monoclonal antibody (mAb) specifically targeting canine interleukin-31. The blocking of IL-31 by lokivetmab prevents IL-31 from binding to its co-receptor and thereby inhibits IL-31 mediated cell signalling, providing relief from Atopic Dermatitis-related pruritus and anti-inflammatory activity.

In a laboratory model study lokivetmab demonstrated an onset of efficacy for pruritus by the first time point at 8 hours post administration.

In field studies up to 9 months, treatment of dogs with atopic dermatitis was demonstrated to have a favourable effect on the reduction of pruritus and on the reduction of disease severity as evaluated by Canine Atopic Dermatitis Extent and Severity Index (CADESI) 03 scores. A small number of dogs showed a low or an absence of clinical response to lokivetmab. This is likely due to the highly targeted mechanism of action of lokivetmab in the context of a complex disease and heterogeneous pathogenesis.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

EU/2/17/205/001-008

30mg » 1ml Vial » Pack of 2

CYTOPOINT® solution for injection for dogs

Presentation

Each vial of 1 ml contains 10, 20, 30 or 40 mg Lokivetmab.

Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.

Uses

Indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For subcutaneous use. Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.

Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer in a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.

Dosage and treatment schedule

The recommended minimum dose is 1 mg/kg bodyweight, once a month. Dose according to the dosing chart below:

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 3 kg bodyweight.

Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.

In cases of atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

It is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.

If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation; therefore its use is not recommended during pregnancy, lactation or in breeding animals.

No drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.

If a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab administration.

Do not mix with any other veterinary medicinal product.

Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases. In such cases appropriate treatment should be administered immediately.

The frequency of adverse reactions is defined using the following convention:

No adverse reactions other than those mentioned above were observed in laboratory overdose studies. In case of adverse clinical signs after an overdose the dog should be treated symptomatically.

User warnings

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection.

Accidental self-injection may result in an immune response to lokivetmab. It is not expected for this to cause any adverse effects, however, repeated self-administration may increase the risk of hypersensitivity reactions.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Store in the original package. Protect from light.

Shelf life after first opening the immediate packaging: use immediately

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in boxes with 2 or 6 single dose vials.

Not all pack sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Not applicable.

Further information

Lokivetmab is a caninised monoclonal antibody (mAb) specifically targeting canine interleukin-31. The blocking of IL-31 by lokivetmab prevents IL-31 from binding to its co-receptor and thereby inhibits IL-31 mediated cell signalling, providing relief from Atopic Dermatitis-related pruritus and anti-inflammatory activity.

In a laboratory model study lokivetmab demonstrated an onset of efficacy for pruritus by the first time point at 8 hours post administration.

In field studies up to 9 months, treatment of dogs with atopic dermatitis was demonstrated to have a favourable effect on the reduction of pruritus and on the reduction of disease severity as evaluated by Canine Atopic Dermatitis Extent and Severity Index (CADESI) 03 scores. A small number of dogs showed a low or an absence of clinical response to lokivetmab. This is likely due to the highly targeted mechanism of action of lokivetmab in the context of a complex disease and heterogeneous pathogenesis.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

EU/2/17/205/001-008

40mg » 1ml Vial » Pack of 2

CYTOPOINT® solution for injection for dogs

Presentation

Each vial of 1 ml contains 10, 20, 30 or 40 mg Lokivetmab.

Lokivetmab is a caninised monoclonal antibody expressed through recombinant techniques in Chinese hamster ovary (CHO) cells.

Uses

Indicated for the treatment of clinical manifestations of atopic dermatitis in dogs.

Dosage and administration

For subcutaneous use. Avoid excessive shaking or foaming of the solution. Administer the entire contents (1 ml) of the vial.

Dose according to the dosing chart below. For dogs above 40 kg, the contents of more than one vial are required to administer in a single dose. In those cases, withdraw the appropriate content from each required vial into the same syringe. To allow for mixing of the solution, gently invert the syringe three or four times before administering.

Dosage and treatment schedule

The recommended minimum dose is 1 mg/kg bodyweight, once a month. Dose according to the dosing chart below:

Contra-indications, warnings, etc

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs less than 3 kg bodyweight.

Lokivetmab may induce transient or persistent anti-drug antibodies. The induction of such antibodies is uncommon and may have no effect (transient anti-drug antibodies) or may result in a noticeable decrease in efficacy (persistent anti-drug antibodies) in animals that responded to treatment previously.

In cases of atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

It is recommended to monitor dogs for bacterial infections associated with atopic dermatitis, especially during the first weeks of treatment.

If no or limited response is observed within one month after initial dosing, an improvement in response may be observed after administration of a second dose one month later. However, if the animal does not show a better response after the second dose, the veterinary surgeon should consider alternative treatments.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation; therefore its use is not recommended during pregnancy, lactation or in breeding animals.

No drug interactions were observed in field studies where lokivetmab was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials, anti-inflammatories and vaccines.

If a vaccine(s) is to be administered at the same time as treatment with lokivetmab, the vaccine(s) should be administered at a different site to that of lokivetmab administration.

Do not mix with any other veterinary medicinal product.

Hypersensitivity reactions (anaphylaxis, facial oedema, urticaria) may occur in rare cases. In such cases appropriate treatment should be administered immediately.

The frequency of adverse reactions is defined using the following convention:

No adverse reactions other than those mentioned above were observed in laboratory overdose studies. In case of adverse clinical signs after an overdose the dog should be treated symptomatically.

User warnings

Hypersensitivity reactions, including anaphylaxis, could potentially occur in the case of accidental self-injection.

Accidental self-injection may result in an immune response to lokivetmab. It is not expected for this to cause any adverse effects, however, repeated self-administration may increase the risk of hypersensitivity reactions.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pharmaceutical precautions

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Store in the original package. Protect from light.

Shelf life after first opening the immediate packaging: use immediately

Keep out of the sight and reach of children.

For animal treatment only.

Legal category

Packaging quantities

Supplied in boxes with 2 or 6 single dose vials.

Not all pack sizes may be marketed.

Marketing Authorisation Holder (if different from distributor)

Not applicable.

Further information

Lokivetmab is a caninised monoclonal antibody (mAb) specifically targeting canine interleukin-31. The blocking of IL-31 by lokivetmab prevents IL-31 from binding to its co-receptor and thereby inhibits IL-31 mediated cell signalling, providing relief from Atopic Dermatitis-related pruritus and anti-inflammatory activity.

In a laboratory model study lokivetmab demonstrated an onset of efficacy for pruritus by the first time point at 8 hours post administration.

In field studies up to 9 months, treatment of dogs with atopic dermatitis was demonstrated to have a favourable effect on the reduction of pruritus and on the reduction of disease severity as evaluated by Canine Atopic Dermatitis Extent and Severity Index (CADESI) 03 scores. A small number of dogs showed a low or an absence of clinical response to lokivetmab. This is likely due to the highly targeted mechanism of action of lokivetmab in the context of a complex disease and heterogeneous pathogenesis.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Number

EU/2/17/205/001-008

Delivery Information

How quickly do you deliver?

Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.

What do you charge for delivery?

For UK delivery, we charge the following:

Order Total Weight Delivery
£0-£28.99 Under 2kg £2.99
2kg+ £4.99
£29-£38.99 Under 2kg Free
2kg+ £4.99
£39+ Under 2kg Free
2kg+ Free

Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.

For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.

We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.

Delivery of aerosols

Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.

Delivery of temperature controlled items

Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.

How do I cancel or return an order?

Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.

To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.

*For full details on returns, see our terms and conditions page.

Reviews

Q & A

There are currently no questions for Cytopoint - be the first to ask one!